SEC Filing Summary: Xenomics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Xenomics, Inc., a Florida corporation, on April 7, 2006, covering events occurring on April 4, 2006. The filing reports a corporate governance change involving the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of Colin J. Foster to the Board of Directors. Mr. Foster was appointed to serve until the next annual meeting of stockholders or until his successor is duly elected and qualified. Prior to this appointment, Mr. Foster served as President and CEO of Bayer Pharmaceuticals Corporation (2002–2004) and held regional leadership roles within Bayer AG.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, risk factors, contingencies, or unusual items. The document includes a reference to a press release dated April 5, 2006, as an exhibit, but the content of that release is not included in the provided text.
Key Facts for Investor Verification
- Colin J. Foster has been appointed to the Xenomics, Inc. Board of Directors effective April 4, 2006.
- Mr. Foster brings significant pharmaceutical industry experience, including former executive roles at Bayer Pharmaceuticals Corporation.
- The filing contains no financial data; investors should refer to the company's most recent 10-K or 10-Q for financial performance.
- Verify the full text of the April 5, 2006 press release (Exhibit 99.1) for additional context on the appointment.